According to the firm, the design of the facility will allow a very high degree of customization of the production process.
The facility is expected to enable cGMP production of all of the company’s several nanoviricide drug candidates, in various delivery forms ranging from injectables, oral, eye drops, to skin creams.
NanoViricides is a US-based nanomaterials company, which is currently developing an injectable anti-influenza drug, NV-INF-1, towards IND-enabling studies.
The firm is also developing an oral broad-spectrum anti-influenza drug candidate, NV-INF-2.